Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
In HER2-mutant non-small cell lung cancer, the DESTINY-Lung02 trial established that starting trastuzumab deruxtecan at 5.4 mg/kg instead of 6.4 mg/kg cuts interstitial lung disease rates from 32% down to 15%. Because antitumor efficacy and response rates remain equivalent between both doses, 5.4 mg/kg represents the necessary standard to minimize potentially fatal pulmonary toxicity.
Related Insights
Trastuzumab deruxtecan (TDXD) and datopotamab deruxtecan (Dato-DXd) share the same cytotoxic payload, yet Dato-DXd has a much lower rate of interstitial lung disease (ILD). This indicates the toxicity is driven by the antibody-antigen interaction, not the payload itself.
A practice gap exists in managing side effects of Trastuzumab-Deruxtecan (TDXD) between specialties. Breast oncologists, with more experience, are far more aggressive with prophylactic anti-emetics and frequent imaging to detect asymptomatic ILD. This proactive approach is a key lesson for lung cancer specialists and others now adopting the drug.
For urothelial cancer patients treated with trastuzumab deruxtecan (TDXD), developing symptomatic (Grade 2) interstitial lung disease or pneumonitis is a critical event. Following protocols from other cancers, this requires permanent discontinuation of the therapy. Re-challenging the patient with TDXD after a Grade 2 event is not recommended without more disease-specific safety data.
In the DESTINY LUNG-02 trial for HER2-mutant NSCLC, the lower 5.4 mg/kg dose of Trastuzumab-Deruxtecan (TDXD) yielded a 51% response rate, compared to 28% for the higher 6.4 mg/kg dose. This paradoxical outcome was driven by significantly higher toxicity, particularly interstitial lung disease (ILD), at the higher dose, which limited patients' ability to stay on treatment.
In the REJOYCE ovarian-1 trial for RDXD, the 5.6 mg/kg dose was selected to move forward over a 6.4 mg/kg dose that showed a higher response rate (57%). The lower dose had significantly fewer serious adverse events and a lower rate of interstitial lung disease (ILD), demonstrating a crucial trade-off where safety and tolerability outweigh peak efficacy in late-stage development.
Interstitial lung disease (ILD) is a serious risk with trastuzumab deruxtecan (TDXD). Oncologists must take it extremely seriously, engaging a pulmonologist immediately at the first sign of symptoms or CT scan findings. A collaborative, multidisciplinary approach is essential for safely managing this potentially fatal toxicity.
In the DESTINY-CRC02 trial, the lower 5.4 mg/kg dose of trastuzumab deruxtecan (TDXD) resulted in a higher response rate in colorectal cancer compared to the 6.4 mg/kg dose used in gastric cancer. This counter-intuitive finding suggests better tolerability led to longer treatment duration and superior outcomes.
The approved dose of trastuzumab deruxtecan (TDXD) for gastric cancer is 6.4 mg/kg, higher and more toxic than in other tumors. Clinicians must use a multi-agent antiemetic cocktail (including NK1 inhibitors and olanzapine) and consider a lower starting dose of 5.4 mg/kg for elderly or poor-performance patients.
To proactively screen for interstitial lung disease (ILD), a serious risk with trastuzumab deruxtecan (TDXD), imaging should be conducted more frequently than the typical 12-week interval. The recommended strategy is to scan patients every nine weeks, or after every three cycles, to identify asymptomatic Grade 1 ILD cases early.
When selecting an ADC dose for pivotal trials, the highest response rate is not the sole driver. Developers prioritize the best balance of efficacy and toxicity, often choosing a dose with slightly lower response but significantly fewer serious adverse events, discontinuations, and specific risks like ILD.
